Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial TumorsStéphanie Decary(Sanofi (France)), Véronique Blanc(Sanofi (France))Clinical Cancer ResearchOctober 12, 202010.1158/1078-0432.ccr-19-4051Cited by 79SaveCiteExport RISWatch citationsRelated PapersAbstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system|Cancer Research|2021|1